Case Study: Rapid Sourcing of Discontinued Southern Hemisphere Vaccine for a Global Biopharmaceutical Client

Client Request

A leading global biopharmaceutical company approached CSI with an urgent need for the Fluarix QIV Southern Hemisphere Vaccine 2025. The requirements included:

• Quantity: 10,000 doses

• Delivery Date: As soon as possible (urgent)

• Delivery Location: Singapore

• Batch Preference: Multiple lots acceptable if necessary

  
  

The Challenge

The client was let down by a supplier in Brazil and needed to secure alternative stock at the last minute. Complicating matters, the Fluarix QIV Southern Hemisphere vaccine had been discontinued in many markets, significantly limiting global availability. Timing was critical, as vaccine allocations were closing and stock was being committed through pre-bookings.

CSI’s Solution

CSI acted immediately to onboard the client rapidly, understanding the urgency and complexity of the request. Within just one week of initial contact, CSI identified a secure supply of the correct Southern Hemisphere strain of the vaccine, also working to obtain this in a single batch. The opportunity to secure the stock was limited, requiring pre-booking within days to avoid the doses being allocated elsewhere.

Thanks to CSI’s agility, experienced market access and expertise in comparator sourcing, the client was successfully onboarded in record time and the stock was secured and delivered on time.

Outcome

Following the initial successful delivery, the client requested additional doses. While the pre-booking period had closed and most stock had been allocated, CSI continued to monitor regional availability. By working closely with local marketing authorization holders, CSI was able to secure an additional 2,000 units as bookings began to release — ensuring the client’s continued access to this hard-to-source vaccine.

Client Impact

The client was highly satisfied with the speed, professionalism and outcome of CSI’s service and has since engaged CSI for further sourcing support.